ORION CORPORATION INVESTOR NEWS 21 MAY 2025 at 07.30 EEST Orion’s collaborator, MSD, expands clinical development program for opevesostat to women’s cancers Orion’s collaborator, MSD, has ...

Evaxion Biotech. Agreement provides MSD with options to license Evaxion’s preclinical, AI-designed vaccine candidates EVX-B2 and EVX-B3. Evaxion will host a conference call and webcast to ...

Evaxion and MSD reach vaccine development milestone. View all comments (0) 0. Latest comments. Post. Comment Guidelines. Trade With A Regulated Broker. Indices. Commodities. Bonds. Stocks. US 30 .

Evaxion Biotech shares gained roughly 17% in early trade on Thursday after the company announced an expansion of its vaccine development collaboration with MSD (NYSE:MRK) (tradename of Merck & Co ...

Cyprumed and MSD sign a Non-Exclusive License and Option Agreement to develop oral formulations of MSD’s peptides using Cyprumed’s technology. ... Cyprumed Enters License and Option Agreement With MSD ...

Orion's collaborator, MSD, has expanded the development program for opevestostat (MK-5684) to now include women's cancers. A new Phase 2 clinical trial evaluating the safety and efficacy of ...

Agreement provides MSD with options to license Evaxion’s preclinical, AI-designed vaccine candidates EVX-B2 and EVX-B3Evaxion will host a conference call and webcast to discuss the agreement on ...

Orion’s collaborator, MSD, has expanded the development program for opevestostat (MK-5684) to now include women’s cancers. A new Phase 2 clinical trial evaluating the safety and efficacy of ...